Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients

The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients. The main question it aims to answer is:

- Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients?

Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Kidney Injury Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hemorrhage Intracranial Hemorrhages Kidney Diseases Male Urogenital Diseases Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Subarachnoid Hemorrhage Urogenital Diseases Urologic Diseases Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Faculty of medicine, Alexandria University

Alexandria, 21648, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient admission to hospital within 48 hours of subarachnoid haemorrhage onset.
Subarachnoid haemorrhage caused by intracranial aneurysm rupture and is confirmed via computed tomography angiography (CTA).
Medical treatment, microsurgical clipping, or interventional endovascular treatment of aneurysm is performed within 48 hours of subarachnoid haemorrhage onset.

Exclusion criteria

Prior onset of subarachnoid haemorrhage or other neurological diseases such as ischemic stroke, hemorrhagic stroke, or severe head trauma.
Systemic diseases, such as chronic liver diseases, chronic lung diseases, chronic heart failure, thyroid diseases and cancer.
Renal impairment at time of admission (creatinine-based eGFR less than 60 ml/min per 1.73 m2 body surface area).
Patients who are hemodynamically unstable at time of admission.
Mortality within 10 days after admission (duration of study).

Treatment and study plan

Cystatin C

Diagnostic Test

a biomarker to assess renal function

Primary outcomes

Acute kidney injury

Time frame: 6 days

stages "risk" and "injury" are considered early AKI

Secondary outcomes

Adverse neurological outcomes

Time frame: 10 days all except mortality within 28 days

Delayed cerebral ischemia Angiographic vasospasm Hydrocephalus Infection Mortality

Sponsors and collaborators

Lead sponsor

Alexandria University

Other

Registry information

Official study title

Cystatin c as a Predictive Biomarker of Acute Kidney Injury and Neurological Outcomes in Aneurysmal Subarachnoid Haemorrhage Patients

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Oct 10, 2024
Registry last updated: Apr 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed